Because when it’s on the line ...

We Lead.

At BioPharma Solutions, we work closely with you at every step to help you achieve your molecule’s full potential and your commercialization objectives — building on over 90 years of innovation, expertise and specialization inparenterals.

Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue